GlassScriptPhysician profile
Emily Bhandare
NPI 1881123966
$6,271.70
in general payments reported to CMS, 2019-2025
46 companies · $1,652 in 2025
The $1,652 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.60 · 2021: $301 · 2022: $813 · 2023: $1,658 · 2024: $1,832 · 2025: $1,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,142.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $801.51 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $678.87 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $597.84 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $591.98 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $368.28 | 2022-2025 | Repatha, Otezla, Otezla |
| Organon LLC | $337.99 | 2022-2025 | Nexplanon |
| Exact Sciences Corporation | $184.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Nevro Corp. | $177.25 | 2022-2024 | Senza |
| Otsuka America Pharmaceutical, INC. | $169.86 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $163.02 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.34 | 2021-2025 | |
| Corcept Therapeutics | $146.44 | 2022-2025 | Korlym |
| Pfizer INC. | $133.15 | 2023-2025 | |
| Glaxosmithkline, LLC. | $125.27 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $123.34 | 2022-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.72 | 2022-2025 | Jardiance |
| Abiomed | $103.31 | 2024-2025 | Impella |
| Sumitomo Pharma America, INC. | $99.62 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $87.12 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $87.04 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.12 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $77.63 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.96 | 2024-2025 | Caplyta |
| Edwards Lifesciences Corporation | $63.64 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mannkind Corporation | $62.12 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $57.70 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $54.47 | 2024 | |
| Lundbeck LLC | $52.47 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $47.22 | 2024-2025 | Spravato |
| Astellas Pharma US INC | $46.30 | 2024 | Veozah |
| Kyowa Kirin, INC. | $44.33 | 2025 | |
| Xeris Pharmaceuticals, INC. | $37.02 | 2024-2025 | Recorlev |
| E.R. Squibb & Sons, L.L.C. | $36.60 | 2025 | Cobenfy, Eliquis |
| Antares Pharma, INC. | $35.00 | 2024-2025 | Xyosted |
| Philips North America LLC | $30.59 | 2023-2024 | (8874) Incourage |
| Csl Behring | $29.89 | 2025 | Hizentra |
| Inspire Medical Systems, INC. | $29.49 | 2025 | Inspire |
| Medtronic, INC. | $28.57 | 2024 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $21.27 | 2024 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $19.08 | 2023 | |
| Embecta Corp. | $18.31 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Biohaven Pharmaceutical Holding Company LTD. | $18.16 | 2022 | |
| Ardelyx, INC. | $17.61 | 2024 | Ibsrela |
| Tactile Systems Technology INC | $16.90 | 2023 | Entre Plus, Flexitouch Plus |
| Axsome Therapeutics, INC. | $15.35 | 2024 | Auvelity |
| Almatica Pharma LLC | $13.28 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bhandare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.